Fosamax is a bisphosphonate medication sold under the name Alendronate sodium, a prescription medicine that is used to treat and prevent bone loss and osteoporosis. Fosamax achieves its purpose of maintaining and increasing bone mineral density by reducing bone resorption, which occurs naturally when old bones are removed by the body. It is used to treat postmenopausal osteoporosis, steroid-induced osteoporosis, low bone mass in men, and Paget's disease of bone. It works by binding to the bone surfaces and inhibiting osteoclasts, which are the cells that break down bone tissue, slowing bone loss and increasing overall bone density. It is an oral medication that is advised not to be taken with antacids and NSAIDs, as it may result in stomach and digestive issues.

Important Warnings while taking Fosamax

There is an association of Fosamax with irritation of the upper gastrointestinal system, and more specifically with irritation of the esophagus. It is essential to pay attention to the administration recommendations since taking the drug incorrectly increases the probability of esophageal irritation. The appearance of new or worsening difficulty with swallowing, chest pain, or heartburn requires consulting a physician. Fosamax is contraindicated in cases of certain esophageal disorders that impair emptying and in individuals unable to stay in an upright position for not less than 30 minutes following drug consumption.

Calcium level in blood needs to be normalized before the start of Fosamax use since this therapy can aggravate the problem. Calcium and vitamin D intake are required during therapy in case of nutrient deficiency from the diet.

Bone, joint, or musculoskeletal pain may occur with bisphosphonate treatment. Osteonecrosis of the jaw has been noted in some individuals on long-term bisphosphonate therapy, as well as in individuals undergoing dental surgery. It is necessary to notify a physician and a dentist about the treatment with Fosamax.

Atypical femur fractures have been noted as well. New or unusual pain in the thigh or groin needs to be medically assessed because this could signal a partial fracture of the femur bone. Re-evaluation of the necessity for continuing treatment should be done from time to time, especially in low-risk patients after many years of treatment.

Things to consider before Fosamax consumption

• Allergies 
• Low calcium levels
• Esophageal or swallowing problems 
• Kidney disease 
• Dental problems or planned dental procedures 
• Bone, joint, or muscle problems 
• Pregnancy and breastfeeding 
• Other medicines and supplements 
• Calcium and vitamin D intake
• Ability to remain upright after taking the medicine
• Existing gastrointestinal conditions 
• Long-term osteoporosis treatment

Fosamax can influence the gastrointestinal system, calcium level, bones, and jaw. Individuals suffering from esophageal disorders or inability to stay upright for a half-hour period of time should not use Fosamax, whereas those patients who suffer from reduced calcium levels should have this problem corrected prior to the start of therapy. It is necessary to test kidney function since Fosamax is not recommended under the mentioned renal function threshold. Individuals should consult with their healthcare specialist regarding the existence of some dental problems and future dental operations, as there is a possibility of osteonecrosis of the jaw. Some drugs, calcium preparations, and antacids can affect the absorption of alendronate; that is why they should be used in a proper time. 

Application/Consumption

The tablets Fosamax must be swallowed whole with plain water right after waking up in the morning and at least half an hour prior to the first food, drink, or other medication intake in the morning. The patient must neither chew nor suck nor crush the tablet. The patient must stay in a sitting or upright position after taking the drug and until the time of the meal.

This is essential because food, beverages other than plain water, calcium, antacids, and some oral medications may reduce alendronate absorption. The medication must not be consumed together with coffee, juice, mineral water, or any other beverages.

In case of once-weekly administration, the drug must be taken on the selected day of the week. In case of missing a weekly dose, the patient needs to take one dose the next morning when the mistake is noted and resume the regular weekly regimen. Two doses must not be taken within one day. Fosamax should be taken exactly as prescribed.

Dosing information

• For treatment of osteoporosis in postmenopausal women, the recommended Fosamax dosage is 70 mg once weekly or 10 mg once daily.
• For treatment to increase bone mass in men with osteoporosis, the recommended dosage is also 70 mg once weekly or 10 mg once daily.
• For prevention of postmenopausal osteoporosis, the recommended dosage is 35 mg once weekly or 5 mg once daily.
• For glucocorticoid-induced osteoporosis, the recommended dosage is 5 mg once daily. A 10 mg daily dose is recommended for postmenopausal women who are not receiving estrogen.
• For Paget's disease of bone, the recommended dosage is 40 mg once daily for six months. Retreatment may be considered after an appropriate post-treatment evaluation if the disease relapses.

The appropriate regimen depends on the condition being treated and the patient's medical history. Fosamax is not indicated for pediatric patients, and renal function should be considered before treatment.

Uses

Fosamax is used for: 

• Postmenopausal osteoporosis: It helps increase bone mass and reduce the incidence of fractures, including hip and vertebral fractures. 
• Prevention of postmenopausal osteoporosis: It is used to help prevent loss of bone mass. 
• Osteoporosis in men: It is used to increase bone mass in men with osteoporosis.
• Glucocorticoid-induced osteoporosis: It is used to treat osteoporosis associated with long-term glucocorticoid therapy. 
• Paget's disease of bone: It helps reduce excessive bone turnover associated with Paget's disease. 

Fosamax is part of a broader osteoporosis-management approach that may also include adequate calcium and vitamin D intake, appropriate physical activity, and measures to reduce fracture risk. 

Fosamax side effects

The common adverse effects seen with the use of Fosamax are abdominal pain, acid reflux, constipation, diarrhea, dyspepsia, musculoskeletal pain, and nausea. The adverse effects may vary from person to person depending on the way the drug is being consumed.

Among the adverse effects, the upper gastrointestinal effects need special attention for the use of Fosamax. The patients may suffer from heartburn, esophageal irritation, difficulty in swallowing, or chest pain. Misadministration, such as consuming the drug without adequate fluid intake or resting within a short while of consumption, can lead to esophageal irritation. 

The patients may suffer from severe bone, joint, and muscle pain with the use of bisphosphonates. Patients who have severe and persistent musculoskeletal pain need to consult their healthcare professional for proper evaluation.

Osteonecrosis of the jaw is a rare but serious adverse effect caused by bisphosphonates. This condition includes delayed healing or exposure of bone in the jaw and is more often seen among patients who use Fosamax for cancer-related conditions or have other risk factors. Proper oral hygiene can help in managing this condition.

Another uncommon complication of prolonged treatment with bisphosphonates is atypical femoral fractures. Patients complaining of sudden thigh or groin pain should undergo medical examination, as the symptom may occur prior to the development of the fracture. Atypical fractures of the femur are one of the complications listed under the warnings and precautions for the 2026 Fosamax prescribing information.

Fosamax may lead to increased severity of hypocalcemia. Signs of severe hypocalcemia include spasms, tingling, numbness, and abnormal muscle movements. Hypocalcemia correction before therapy and ensuring calcium and vitamin D intake are important factors.

Supplements containing calcium, antacids, and drugs containing multivalent cations have an inhibitory effect on alendronate absorption. They must not be consumed concomitantly with Fosamax. Nonsteroidal anti-inflammatory drugs and aspirin can irritate the stomach along with alendronate; therefore, patients should discuss taking these drugs regularly with a healthcare provider. 

Also, the renal condition needs to be taken into account since Fosamax is excreted via the kidneys and it is not advisable for patients who have a creatinine clearance rate less than 35 mL/min.

For prolonged therapy, regular assessment is needed. It has not yet been established how long Fosamax should be taken, although it is stated in the prescribing information that if patients are at low risk for fractures, they should discontinue treatment after three to five years and then have a re-assessment done on them.